Gut Microbiota’s role in lipoma development: evidence from mendelian randomization DOI Creative Commons
Yuxin Li, Jiahao Chen, Hang Yao

et al.

Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 15, 2024

Background Lipoma, a benign tumor derived from mesenchymal tissue, significantly affects patients’ physical and psychological wellbeing. Increasing evidence points to strong link between the gut microbiome (GM) lipoma incidence. This study utilizes Mendelian Randomization (MR) assess potential causal relationships GM development. Methods We conducted two-sample MR analysis using genome-wide association (GWAS) data MiBioGen FinnGen explore relationship lipoma. The dataset included 18,340 participants with 14,587 single nucleotide polymorphisms (SNPs), while comprised 412,181 21,306,349 SNPs. employed 5 methods: Inverse Variance Weighted (IVW), Median, Simple Mode, MR-Egger, Mode. Additional assessments Cochran’s Q test for result heterogeneity, PRESSO horizontal pleiotropy, sensitivity analyses through scatter plots, leave-one-out analyses, funnel forest plots. Results IVW method identified 18 gene predictors trans-genus associated risk. Protective effects against (BL) were observed in Eubacterium rectale group, Desulfovibrio, Ruminococcus1, Clostridium sensu stricto1, Lachnospiraceae UCG001; conversely, UCG008 was linked increased BL Desulfovibrio provided protection TS-BL; however, Family XIII AD3011 coprostanoligenes NK4A136 Parasutterella an TS-BL innocuum Anaerotruncus, Ruminiclostridium6, UCG001 offered LS-BL, LS-BL brachy Odoribacter, Butyricimonas, Subdoligranulum, stricto1 protective HFNS-BL; Ruminococcaceae UCG005 HFNS-BL Conclusion Compared malignant tumors, research on lipomas has been relatively limited. study, analysis, new of specific development lipomas. Certain bacterial species may act as or harmful factors formation, offering avenues future treatment strategies. However, additional is required unravel complexity how influences pathogenesis

Language: Английский

Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity DOI Creative Commons
Nikolay K. Shakhpazyan, Л.М. Михалева, A.L. Bedzhanyan

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(17), P. 1437 - 1437

Published: Aug. 27, 2024

The gut microbiota plays an essential role in maintaining immune homeostasis and influencing the landscape within tumor microenvironment. This review aims to elucidate interactions between dynamics, with a focus on colorectal cancer (CRC). spans foundational concepts of immuno-microbial interplay, factors microbiome composition, evidence linking immunotherapy outcomes. Gut modulates anti-cancer immunity through several mechanisms, including enhancement surveillance modulation inflammatory responses. Specific microbial species their metabolic byproducts can significantly influence efficacy immunotherapies. Furthermore, diversity correlates clinical outcomes CRC, suggesting potential as valuable biomarker for predicting response immunotherapy. Conclusions: Understanding relationship responses offers novel therapeutic strategies development. not only influences natural history treatment CRC but also serves critical modulator activity. Further exploration into microbiome's could enhance effectiveness existing treatments guide development new modalities.

Language: Английский

Citations

10
The influence of the gut microbiota on B cells in autoimmune diseases DOI Creative Commons

Lun He,

Xin Li, Shan Jiang

et al.

Molecular Medicine, Journal Year: 2025, Volume and Issue: 31(1)

Published: April 22, 2025

Abstract Mounting evidence shows that gut microbiota communities and the human immune system coexist influence each other, there are a number of reports correlation between specific changes in occurrence autoimmune diseases. B lymphocytes play central role regulation both Here, we summarize microbiota-B cell pathways on diseases how cells regulate microorganisms, which provides mechanistic insights with relevance for identification potential therapeutic targets related fields.

Language: Английский

Citations

0
Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment DOI Creative Commons
Esther Ugo Alum,

Daniel Ejim Uti,

Okechukwu Paul-Chima Ugwu

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 30, 2025

The human microbiota comprises a diverse microbial ecosystem that significantly impacts health and disease. Among its components, the gut plays crucial role in regulating metabolic, immunologic, inflammatory responses. Dysbiosis, an imbalance composition, has been linked to carcinogenesis through mechanisms such as chronic inflammation, metabolic disturbances, epigenetic modifications, immune system dysregulation. Additionally, dysbiosis influences efficacy toxicity of cancer therapies. Given these associations, there is growing interest leveraging biomarker for detection outcome prediction. Notably, distinct signatures have identified across various types, suggesting their potential diagnostic markers. Furthermore, modulation presents promising avenue improving treatment outcomes strategies antibiotics, prebiotics, probiotics, fecal transplantation, dietary interventions, small-molecule inhibitors, phage therapy. To explore relationships, we conducted comprehensive literature review using Web Science, Scopus, PubMed, MEDLINE, Embase, Google Scholar our primary online databases, focusing on indexed peer-reviewed articles up present year. This aims elucidate development, examine molecular involved, assess impact highlight microbiota-based therapeutic discuss applications management. A deeper understanding intricate interplay between may pave way novel approaches prevention, early detection, optimization.

Language: Английский

Citations

0
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges DOI Creative Commons
Marco Palma

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 344 - 344

Published: March 24, 2025

Breast cancer (BC) remains a significant global health challenge due to its complex biology, which complicates both diagnosis and treatment. Immunotherapy vaccines have emerged as promising alternatives, harnessing the body’s immune system precisely target eliminate cells. However, several key factors influence selection effectiveness of these therapies, including BC subtype, tumor mutational burden (TMB), tumor-infiltrating lymphocytes (TILs), PD-L1 expression, HER2 resistance, microenvironment (TME). subtypes play critical role in shaping treatment responses. Triple-negative breast (TNBC) exhibits highest sensitivity immunotherapy, while HER2-positive hormone receptor-positive (HR+) often require combination strategies for optimal outcomes. High TMB enhances responses by generating neoantigens, making tumors more susceptible checkpoint inhibitors (ICIs); whereas, low may indicate resistance. Similarly, elevated TIL levels are associated with better immunotherapy efficacy, expression serves predictor inhibitor success. Meanwhile, resistance an immunosuppressive TME contribute evasion, highlighting need multi-faceted approaches. Current immunotherapies encompass range targeted treatments. HER2-directed such trastuzumab pertuzumab, block dimerization enhance antibody-dependent cellular cytotoxicity (ADCC), small-molecule inhibitors, like lapatinib tucatinib, suppress signaling curb growth. Antibody–drug conjugates (ADCs) improve targeting coupling monoclonal antibodies cytotoxic agents, minimizing off-target effects. ICIs, pembrolizumab, restore T-cell function, CAR-macrophage (CAR-M) therapy leverages macrophages reshape overcome While particularly TNBC, has demonstrated promise eliciting durable responses, efficacy varies across subtypes. Challenges immune-related adverse events, mechanisms, high costs, delayed remain barriers widespread vaccines—including protein-based, whole-cell, mRNA, dendritic cell, epitope-based vaccines—aim stimulate tumor-specific immunity. Though clinical success been limited, ongoing research is refining vaccine formulations, integrating identifying biomarkers improved patient stratification. Future advancements will depend on optimizing through biomarker-driven approaches, addressing heterogeneity, developing innovative therapies By leveraging strategies, researchers aim ultimately

Language: Английский

Citations

0
Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes? DOI Open Access
Sultana Mehbuba Hossain, Kevin Ly, Yih Jian Sung

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10120 - 10120

Published: Sept. 20, 2024

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma. However, over 50% of patients experience limited or no response to ICI therapy. Resistance ICIs is influenced a complex interplay tumour intrinsic and extrinsic factors. This review summarizes current for melanoma the factors involved resistance treatment. We also discuss emerging evidence that microbiota can impact outcomes modulating biology function. Furthermore, profiles may offer non-invasive method predicting response. Therefore, future research into manipulation could provide cost-effective strategies enhance improve patients.

Language: Английский

Citations

2
The importance of the microbiome in hematooncology patients DOI

Lucie Dlouhá

Onkologie, Journal Year: 2024, Volume and Issue: 18(2), P. 116 - 120

Published: May 3, 2024

Role některých konkrétních bakterií, jako je např. Helicobacter pylori, v etiologii a patogenezi lymfomu již dlouho známá, ale posledních letech se ukazuje význam mikrobiomu (tvořen 1013 až 1018 mikroby, které osidlují lidské tělo). Vliv celého spočívá regulaci imunitního systému ať přímým působením, nebo prostřednictvím produkovaných metabolitů. Z přibývajících dat vyplývá, že složení střevní mikrobioty podílí na celé řadě onemocnění včetně nádorových. U pacientů s hematologickými malignitami často pozorována snížená druhová diverzita rozdílné oproti zdravým kontrolám. Některé bakterie jsou také spojovány komplikacemi či odpovědí léčbu. Význam těchto bakterií roste zejména širším použitím imunoterapie, jejíž efektivitě hraje důležitou roli funkční imunitní systém. V následujících řádcích zaměřujeme úlohu hematologických malignit jeho ovlivnění protinádorové terapie u nádorů.

Citations

0
Bacteria beneficially alter the tone of immune responses against tumors DOI
Luis Vitetta, Stephen Clarke

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Citations

0
Bacteria beneficially alter the tone of immune responses against tumors DOI
Luis Vitetta, Stephen Clarke

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Citations

0
Gut Microbiota’s role in lipoma development: evidence from mendelian randomization DOI Creative Commons
Yuxin Li, Jiahao Chen, Hang Yao

et al.

Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 15, 2024

Background Lipoma, a benign tumor derived from mesenchymal tissue, significantly affects patients’ physical and psychological wellbeing. Increasing evidence points to strong link between the gut microbiome (GM) lipoma incidence. This study utilizes Mendelian Randomization (MR) assess potential causal relationships GM development. Methods We conducted two-sample MR analysis using genome-wide association (GWAS) data MiBioGen FinnGen explore relationship lipoma. The dataset included 18,340 participants with 14,587 single nucleotide polymorphisms (SNPs), while comprised 412,181 21,306,349 SNPs. employed 5 methods: Inverse Variance Weighted (IVW), Median, Simple Mode, MR-Egger, Mode. Additional assessments Cochran’s Q test for result heterogeneity, PRESSO horizontal pleiotropy, sensitivity analyses through scatter plots, leave-one-out analyses, funnel forest plots. Results IVW method identified 18 gene predictors trans-genus associated risk. Protective effects against (BL) were observed in Eubacterium rectale group, Desulfovibrio, Ruminococcus1, Clostridium sensu stricto1, Lachnospiraceae UCG001; conversely, UCG008 was linked increased BL Desulfovibrio provided protection TS-BL; however, Family XIII AD3011 coprostanoligenes NK4A136 Parasutterella an TS-BL innocuum Anaerotruncus, Ruminiclostridium6, UCG001 offered LS-BL, LS-BL brachy Odoribacter, Butyricimonas, Subdoligranulum, stricto1 protective HFNS-BL; Ruminococcaceae UCG005 HFNS-BL Conclusion Compared malignant tumors, research on lipomas has been relatively limited. study, analysis, new of specific development lipomas. Certain bacterial species may act as or harmful factors formation, offering avenues future treatment strategies. However, additional is required unravel complexity how influences pathogenesis

Language: Английский

Citations

0